Curriculum Vitae - UNC Eshelman School of Pharmacy€¦ · Curriculum Vitae . Joel F. Farley, ... (Chapter 6) in Principles of ... 2. Lauffenburger JC, Farley JF, Gehil AK, Rhoney

8/4/2015

1

Curriculum Vitae

Joel F. Farley, Ph.D. ___ PERSONAL INFORMATION Work Address: UNC Eshelman School of Pharmacy 2205 Kerr Hall, Campus Box 7573, Chapel Hill, NC 27599-7573 Phone: (919) 966-9973 Fax: (919) 966-8486 Email: [email protected] EDUCATION AND TRAINING April 2006 Doctor of Philosophy University of Minnesota, Minneapolis, MN Social, Administrative, and Clinical Pharmacy Advisors: Jon C. Schommer PhD & Richard R. Cline PhD Thesis title: An examination of unintended consequences and policy

effectiveness in prescription prior authorization programs. May 1997 Bachelor of Science Pharmacy University of Wisconsin, Madison, WI Professional Licensure 1997 to present New Mexico Board of Pharmacy (active) 2001 to 2006 Minnesota Board of Pharmacy (inactive) PROFESSIONAL EXPERIENCE 2014 to present University of North Carolina at Chapel Hill, UNC Eshelman School of

Pharmacy, Center for Medication Optimization through Practice and Policy – Interim Director

2012 to present University of North Carolina at Chapel Hill, UNC Eshelman School of Pharmacy, Division of Pharmaceutical Outcomes and Policy – Associate Professor

2006 to 2012 University of North Carolina at Chapel Hill, UNC Eshelman School of Pharmacy, Division of Pharmaceutical Outcomes and Policy – Assistant Professor

2004 to 2006 University of Minnesota - Managed Care Pharmaceutical Outcomes Dissertation Fellow

2001 to 2006 Walgreens, Minneapolis, MN – Relief Pharmacist 2001 to 2004 University of Minnesota, Minneapolis, MN – Research Assistant / Teaching Assistant 2000 to 2001 Walgreens, Las Cruces, NM – Staff Pharmacist 1998 to 2000 Family Pharmacy, Las Cruces, NM – Pharmacy Manager 1997 to 1998 American Drug Stores, Las Cruces, NM – Staff Pharmacist

mailto:[email protected]

8/4/2015

2

1995 to 1997 Walgreens, Madison, WI – Pharmacist Intern HONORS AND AWARDS 2014 American Association of Colleges of Pharmacy Academic Leadership

Fellow 2014 Fellow: American Pharmacists Association 2013 – 2018 Research Fellow. Cecil G Sheps Center for Health Services Research.

University of North Carolina 2009 Best Poster Research Presentation Award. International Society for

Pharmacoeconomics and Outcomes Research 14th Annual International Meeting.

2005 – 2006 Albert I. Wertheimer Leadership in Social and Administrative Pharmacy Fellowship Award

2005 International Society for Pharmacoeconomics and Outcomes Research Distinguished Service Award

2004 – 2006 Pfizer Managed Care Pharmaceutical Outcomes Dissertation Fellowship 2004 – 2005 American Foundation for Pharmaceutical Education Pre-doctoral

Fellowship 2003 – 2004 American Foundation for Pharmaceutical Education Pre-doctoral

Fellowship BOOKS AND CHAPTERS 1. Farley, Joel F. (2014) “Other Observational Study Designs” (Chapter 6) in Principles of

Research Design and Drug Literature Evaluation by Rajender R. Aparasu (Editor) and John P. Bentley (Editor), Jones and Bartlet Learning, Burlington, MA.

2. Domino, Marisa Elena and Farley, Joel F. (2010). "Economic Issues in Psychotropic Medication use." (pp. 481-498) In Mental Health Services: A Public Health Perspective, Ed.3 by Bruce Lubotsky Levin (Editor), Kevin D. Hennessy (Editor), John Petrila (Editor), Oxford University Press, Oxford.

PEER REFEREED PUBLICATIONS

1. Wang CC. Wu CH, Farley JF. (2015) “Patterns of osteoporosis treatment among patients qualified for pharmacological treatment according to the National Osteoporosis Foundation guidelines.” Annals of Pharmacotherapy. Epub ahead of print: http://aop.sagepub.com/content/early/2015/05/26/1060028015588127.full.pdf

2. Lauffenburger JC, Farley JF, Gehil AK, Rhoney DH, Brookhart MA, Fang G. (2015) “Predictors of gastrointestinal bleeding among patients with atrial fibrillation initiating dabigatran”. Pharmacotherapy. (In press)

3. Amin K, Farley JF, Maciejewski ML, Domino ME. (2015) “ Impact of Medicaid policy changes on medication adherences by baseline adherence”. Journal of Managed Care Pharmacy. (In press)

http://aop.sagepub.com/content/early/2015/05/26/1060028015588127.full.pdf

8/4/2015

3

4. Lauffenburger JC, Farley JF, Gehil AK, Rhoney DH, Brookhart MA, Fang G. (2015) “Effectiveness and safety of dabigitran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study.” Journal of the American Heart Association. Epub ahead of print: http://www.ncbi.nlm.nih.gov/pubmed/25862791 . (PMID:25862791)

5. Lauffenburger JC, Farley JF, Gehil AK, Rhoney DH, Brookhart MA, Fang G. (2015) “Factors driving anticoagulant selection in patient with atrial fibrillation in the United States”. American Journal of Cardiology. 115(8):1095-1101.(PMID:4380530)

6. Overman RA, Gourlay ML, Deal CL, Farley JF, Brookhart A, Layton JB. (2015) “Fracture rate associated with quality metric-based anti-osteoporosis treatment in glucocorticoid-induced osteoporosis” Osteoporosis International. 26(5):1515-1524. (PMID:4401629)

7. Beadles CA, Ellis AR, Lichstein JC, Farley JF, Jackson C, Morrissey JP, Domino ME. (2015) “First Outpatient Follow-up after Psychiatric Hospitalization: Does one size fit all?” Psychiatric Services. 66(4):364-372. (PMID:25828981)

8. Overman RA, Farley JF, Curtis JR, Zhang J, Gourlay ML, Deal CL. (2015) “DXA Utilization Between 2006 and 2012 in Commercially Insured Younger Postmenopausal Women” Journal of Clinical Densitometry. 18(2):145-149. (PMID: 4420644)

9. Hansen RA, Voils CI, Farley JF, Powers BJ, Sanders LL, Sleath BL, Maciejewski ML. (2015) “Prescriber continuity and medication adherence for complex patients”. Annals of Pharmacotherapy. 49(3):293-302. (PMID:25549627)

10. Roberts AW, Dusetzina SB, Farley JF. (2015) “Revisiting the washout period in the incident user study design: Why 6 to 12 months may not be sufficient” Journal of Comparative Effectiveness Research. 4 (1):27-35. (PMID:25565067)

11. Beadles CA, Farley JF, Ellis AR, Lichstein JC, Morrissey JP, DuBard AC, Domino ME. (2015) “Do medical homes increase medication adherence for persons with multiple chronic -conditions” Medical Care. 53(2):168-176. (PMID:25517069)

12. Beadles CA, Voils CI, Crowley MJ, Farley JF, Maciejewski ML. (2014) “Continuity of medication management and continuity of care: Conceptual and operational considerations” Sage Open Medicine. http://smo.sagepub.com/content/2/2050312114559261

13. Desai RJ, Rao JK, Hansen RA, Fang G, Maciejewski ML, Farley JF*. (2014) “Predictors of treatment initiation with tumor necrosis factor-α inhibitors in patients with rheumatoid arthritis.” Journal of Managed Care Pharmacy. 20(11):1110-1120. (PMID:25351972)

14. Desai RJ, Rao JK, Hansen RA, Fang G, Maciejewski ML, Farley JF*. (2014) “TNF-alpha inhibitor treatment and the risk of incident cardiovascular events in patients with early rheumatoid arthritis: a nested case-control study”. The Journal of Rheumatology. 41(11):2129-2136.

15. Lauffenburger JC, Mayer CL, Hawke RL, Brouwer KL, Fried MW, Farley JF*. (2014) “Medication use and medical comorbidity in patients with chronic hepatitis C from a U.S. commercial claims database: High utilization of drugs with interaction potential.” European Journal of Gastroenterology and Hepatology. 26(10):1073-1082. (PMID:250114625)

http://www.ncbi.nlm.nih.gov/pubmed/25862791

http://smo.sagepub.com/content/2/2050312114559261

8/4/2015

4

16. Maciejewski ML, Powers BJ, Sanders LL, Farley JF, Hansen RA, Sleath BL, Voils CI. (2014) “The Intersection of Patient Complexity, Prescriber Continuity and Acute Care Utilization” Journal of General Internal Medicine. 29(4):594-601.(PMID:24408277)

17. Roberts AW, Crisp GD, Esserman DA, Roth MT, Weinberger M, Farley JF*. (2014) “Patterns of Medication Adherence and Healthcare Utilization among Charitable Pharmacy Assistance Program Members with Chronic Disease”. North Carolina Medical Journal. 75(5):310-318. (PMID:25237868)

18. Crisp GD, Roberts AW, Esserman DA, Roth MT, Weinberger M, Farley JF*. (2014) “The UNC Health Care Pharmacy Assistance Program.” North Carolina Medical Journal. 75(5):303-309. (PMID:25237867)

19. Domino ME, Beadles CA, Lichstein JC, Farley JF, Morrissey JP, Ellis AR, DuBard CA. (2014) “Heterogeneity in the Quality of Care for Patients with Multiple Chronic Conditions by Psychiatric Comorbidity.” Medical Care. 53(Suppl3):S101-109. (PMID:24561748)

20. Lichstein JC, Domino ME, Beadles CA, Ellis AR, Farley JF, Morrissey JP, Gauchat GW, DuBard AC, Jackson C. (2014) “Use of medical homes by patients with comorbid physical and severe mental illness.” Medical Care. 53(Suppl3):S85-91. (PMID: 24561764)

21. Maciejewski ML, Wansink D, Lindquist JH, Parker JC, Farley, JF. (2014) “Value-Based Insurance Design Program In North Carolina Increased Medication Adherence But Was Not Cost Neutral” Health Affairs. 33(2):300-308. (PMID:24493774)

22. Daugherty JB, Maciejewski ML, Farley JF. (2013) “The impact of manufacturer coupons in the statin market.” Journal of Managed Care Pharmacy. 19(9):765-772. (PMID: 24156645)

23. Wang CC, Maciejewski ML, Rao JK, Sheitman BB, Sleath BL, Farley JF. (2013) “Examining the relationship between adjunctive psychotherapy and antipsychotic persistence and hospitalization.” Administration and Policy in Mental Health. 41(5):598-607. (PMID: 23733044)

24. Lauffenburger JC, Balasubramanian A, Farley JF, Critchlow CW, O’Malley CD, Roth MT, Pate V, Brookhart MA. (2013) “Completeness of prescription information in US commercial claims databases”. Pharmacoepidemiology and Drug Safety. 22(8):899-906. (PMID: 23696101)

25. Hansen RA, Farley JF, Maciejewski ML, Ye X, Qian C, Powers B. (2013) “Real-world utilization patterns and outcomes of colesevelam hcl in the GE electronic medical record” BMC Endocrine Disorders. Published online at: http://www.biomedcentral.com/1472-6823/13/24 (PMID: 23866087)

26. Christian RB, Farley JF, Sheitman B, McKee JR, Wei D, Diamond J, Chrisman A, Barnhill LJ, Wegner L, Palmes G, Trygstad T, Pfeiffenberger T, Wegner SE, Best R, Sikich L. (2013) “A+Kids, A Web-based Registry for North Carolina Youth: An Alternative to Prior Authorization” Psychiatric Services. 64(9):893-900. (PMID: 23728296)

27. Wang CC, Farley JF. (2013) “Patterns and predictors of antipsychotic medication use among the U.S. population: Findings from the Medical Expenditure Panel Survey (MEPS).” Research in Social and Administrative Pharmacy. 9(3):263-275. (PMID: 21272525)

28. Ellis AR, Dusetzina SB, Hansen RA, Gaynes BN, Farley JF, Sturmer T. (2013) “Confounding control in a non-experimental study of STAR*D data: Logistic regression

http://www.biomedcentral.com/1472-6823/13/24

http://www.biomedcentral.com/1472-6823/13/24

8/4/2015

5

balanced covariates better than boosted CART.” Annals of Epidemiology. 23(4):204-209. (PMID: 23419508)

29. Wu CH, Wang CC, Katz AJ, Farley JF. (2013) “National trends of psychotropic medication use among patients diagnosed with anxiety disorders: Results from Medical Expenditure Panel Survey 2004-2009” Journal of Anxiety Disorders. 27(2):163-170 (PMID: 23428605)

30. Ellis AR, Dusetzina SB, Hansen RA, Gaynes, BN, Farley JF, Sturmer T. (2013) “Investigating differences in treatment effect estimates between propensity score matching and weighting: A demonstration using STAR*D trial data” Pharmacoepidemiology and Drug Safety. 22(2):138-144. (PMID: 23280682)

31. Wang CC, Wei D, Farley JF. (2013) “Impact of monthly prescription cap on medication persistence among patients with hypertension.” Journal of Managed Care Pharmacy. 19(3):258-268. (PMID: 23537460)

32. Farley JF, Weeks L, Wegner SE. (2013) “The A+KIDS Program” Psychiatric Services. 64(1): 98-99. (PMID: 23280465)

33. Dusetzina SB, Weinberger M, Sleath B, Gaynes BN, Farley JF, Hansen RA. (2012) “Prevalence of Bipolar Disorder Diagnoses and Medication Use among Privately Insured Youth.” Pharmacotherapy. 32(12):1085-1094 (PMID: 23208835)

34. Branham AR, Katz AJ, Moose J, Ferreri S, Farley JF, Marciniak MW. (2012) “Retrospective analysis of cost avoidance following pharmacist-provided medication therapy management services”. Journal of Pharmacy Practice. Published online first at: http://jpp.sagepub.com/content/early/2012/11/19/0897190012465992.abstract (PMID: 23178415)

35. Gaynes B, Dusetzina SB, Ellis AR, Hansen RA, Farley JF, Sturmer T. (2012) “Does the presence of accompanying symptom clusters differentiate the comparative effectiveness of second-line medication strategies for treating depression?” Depression and Anxiety. 28(11):989-998. (PMID: 21898717)

36. Hansen RA, Dusetzina SB, Ellis AR, Sturmer T, Farley JF, Gaynes BN. (2012) “Risk of adverse events in treatment resistant depression: propensity-score-matched comparison of antidepressant augment and switch strategies.” General Hospital Psychiatry. 34(2):192-200. (PMID: 22079151)

37. Wu CH, Farley JF, Gaynes BN (2012). “The association between antidepressant dosage titration and medication adherence among patients with depression”. Depression and Anxiety. 29(6):506-514. (PMID: 22553149)

38. Dusetzina SB, Farley JF, Weinberger M, Gaynes BN, Sleath B, Hansen RA. (2012) “Treatment Use and Costs among Privately-Insured Youth with Bipolar Diagnoses”. Psychiatric Services. 63(10):1019-1025. (PMID: 22855210)

39. Maciejewski ML, Winegar DA, Farley JF, Wolfe BM. (2012) “Risk stratification of serious adverse events following gastric bypass in the bariatric outcomes longitudinal database”. Surgery for Obesity and Related Diseases. 8(6):671-677. (PMID: 23058451)

40. Butler MG, Farley JF, Murray MD, Sleath BL, Maciejewski ML. (2012) “Medicare Part D Information-Seeking: The Role of Recognition of Need and Patient Activation.” Research in Social and Administrative Pharmacy. 8(5):433-442. (PMID: 22296720)

http://jpp.sagepub.com/content/early/2012/11/19/0897190012465992.abstract

8/4/2015

6

41. Hansen RA, Maciejewski ML, Yu-Isenberg K, Farley JF. (2012) “Adherence to antipsychotics and cardiometabolic medication association with health care utilization and costs.” Psychiatric Services. 63(9):920-928 (PMID: 22706887)?)

42. Wu CH, Farley JF, Gaynes BN. (2012) “Evaluating the association of initial benzodiazepine use and antidepressant adherence among adults with anxiety disorders.” Journal of Experimental and Clinical Medicine. 4(6):338-344.

43. Farley JF*, Hansen RA, Yu-Isenberg KS, Maciejewski ML. (2012) “Antipsychotic adherence and its correlation to health outcomes for chronic comorbid conditions” The Primary Care Companion for CNS Disorders. Published online at http://article.psychiatrist.com/?ContentType=START&ID=10007931.me (PMID: 23106028)

44. Farley JF*, Wansink D, Lindquist JH, Parker JC, Maciejewski ML. (2012) “Medication Adherence Changes following Value Based Insurance Design (VBID)” American Journal of Managed Care. 18(5):41-50. (PMID: 22694064)

45. Gaynes B, Dusetzina SB, Ellis AR, Hansen RA, Farley JF, Sturmer T. (2012) “Treating depression after initial treatment failure: Directly comparing switch and augmenting strategies in STAR*D.” Journal of Clinical Psychopharmacology. 32(1):114-119 (PMID: 22198447)

46. Katz AJ, Dusetzina SB, Farley JF, Ellis AR, Gaynes BN, Castillo WC, Sturmer T, Hansen RA. (2012) “Distressing adverse events after antidepressant switch in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial: influence of adverse events during initial treatment with citalopram on development of subsequent adverse events with an alternative antidepressant.” Pharmacotherapy. 32(3):234-243. (PMID: 22392456) (???)

47. Dorn S, Wei D, Farley JF, Shah ND, Shaheen NJ, Sandler RS, Kappelman MD. (2012) “Impact of the 2008-2009 Economic Recession on Screening Colonoscopy Utilization among the Insured” Clinical Gastroenterology and Hepatology. 10(3):278-284. (PMID: 22155558)

48. Dusetzina SB, Gaynes BN, Weinberger M, Farley JF, Sleath BL, Hansen RA. (2011) “Receipt of guideline concordant pharmacotherapy among children with new bipolar diagnoses.” Psychiatric Services .62:1443-1449. (PMID: 22193791)

49. Farley JF*, Wang CC, Hansen RA, Voils CI, Maciejewski ML. (2011) “Continuity of Antipsychotic Medication Management for Medicaid Patients with Schizophrenia” Psychiatric Services. 62(7):747-752. (PMID: 21724787)

50. Chen SY, Hansen RA, Farley JF, Gaynes BN, Morrissey JP, Maciejewski ML. (2010) “Guideline-concordant antidepressant use among patients with major depressive disorder. General Hospital Psychiatry.” 32(4):360-367. (PMID: 20633739)

51. Maciejewski ML, Farley JF, Parker J, Wansink D. (2010) “Copayment Reductions Generate Greater Medication Adherence in Targeted Patients” Health Affairs. 29(11):2002-8. (PMID: 21041739)

52. Farley JF*, Wang CC, Blalock SJ. (2010) The status of Ph.D. education in Economic, Social, and Administrative Sciences between 2005 and 2008. American Journal of Pharmacy Education. 74(7): Article 126. (PMID: 21088732)

53. Hansen RA, Farley JF, Droege M, Maciejewski ML. (2010) “A retrospective cohort study of economic outcomes and adherence to monotherapy with metformin, pioglitazone, or a

http://article.psychiatrist.com/?ContentType=START&ID=10007931.me

8/4/2015

7

sulfonylurea among patients with type 2 diabetes mellitus in the United States from 2003 to 2005.” Clinical Therapeutics. 32(7):1308-1319. (PMID: 20678679)

54. Farley JF*, Dusetzina S. (2010) “Medicaid prescription drug utilization and expenditures following Part D.” Journal of Health Care for the Poor and Underserved. 21(2):715-728. (PMID: 20453368)

55. Farley JF*. (2010) “Medicaid prescription cost containment and schizophrenia: a retrospective examination.” Medical Care. 48(5):440-447. (PMID: 20351586)

56. Domino ME, Farley JF. (2010) “Economic Grand Rounds: Did Medicare Part D improve access to medications?” Psychiatric Services. 61(2):118-120. (PMID: 20123814)

57. Maciejewski ML, Farley JF, Hansen RA, Wei D, Harman JS. (2010) “Part D plan enrollment by uninsured Medicare beneficiaries.” Medical Care. 48(2):183-186. (PMID: 20057332)

58. Chen SY, Hansen RA, Farley JF, Gaynes BN, Morrissey JP, Maciejewski ML. (2010) “Follow-up visits by provider specialty for patients with major depressive disorder initiating antidepressant treatment.” Psychiatric Services. 61(1):81-85. (PMID: 20044424)

59. Dorn SD, Farley JF, Hansen RA, Shah N, Sandler RS. (2009) “Direct-to-consumer and physician promotion of tegaserod correlated with physician visits, diagnoses, and prescriptions.” Gastroenterology. 137(2):518-524. (PMID: 19445943)

60. Farley JF*, Blalock SJ. (2009) “Trends and determinants of prescription medication use for treatment of osteoporosis.” American Journal of Health-System Pharmacy. 66(1): 1191-1201.(PMID: 19535658)

61. Farley JF*, Cline RR, Schommer JC, Hadsall RS, Nyman JA. (2008) “Retrospective assessment of Medicaid step-therapy prior authorization policy for atypical antipsychotic medications”. Clinical Therapeutics. 30(8):1524-1539. (PMID: 18803994)

62. Farley JF*, Blalock SJ, Cline RR. (2008) “Effect of the Women’s Health Initiative on prescription anti-osteoporosis medication utilization”. Osteoporosis International. 19(11):1603-1612. (PMID: 18373048)

63. Farley JF*, Devine JD, Hadsall RS. (2007) “Professional implications of the expansion of pharmacy-based medical clinics”. Journal of the American Pharmacists Association 47(3): 410-413. (PMID: 17510039)

64. Lu YJ, Farley JF, Hansen RA. (2006) “Promotion and market share in the proton pump inhibitor market: A case study”. The Journal of Pharmaceutical Marketing and Management. 17(3/4): 39-59.

65. Farley JF*, Cline RR, Gupta K. (2006) “Racial variation in antiresorptive medications use: results from the 2000 Medical Expenditure Panel Survey (MEPS)”. Osteoporosis International. 17(3): 395-404. (PMID: 16314982)

66. Devine JW, Cline RR, Farley JF. (2006) “Follow-on biologics: competition in the biopharmaceutical marketplace.” Journal of the American Pharmacists Association. 46(2): 193-201. (PMID: 16602229)

67. Farley JF*, Harley CR, Devine JW. (2006) “A comparison of comorbidity measurements to predict health expenditures.” American Journal of Managed Care. 12(2): 110-117. (PMID: 16464140)

8/4/2015

8

68. Devine JW, Farley JF, Hadsall RS. (2005) “Patterns and predictors of prescription medication use in the management of headache.” Headache: The Journal of Head and Face Pain. 45(9):1171-1180. (PMID: 16178947)

69. Cline RR, Farley JF, Hansen RA, Schommer JC. (2005) “Osteoporosis beliefs and antiresorptive medication use.” Maturitas. 50:196-208. (PMID: 15734601)

70. Farley JF*, Cline RR, Hansen RA. (2004) “Resorptive drug use patterns among Minnesota females: results of a statewide survey.” American Journal of Health-System Pharmacy. 61:1577-1585. (PMID: 15372831)

* Papers in which I am listed as the corresponding author PEER REFEREED PODIUM PRESENTATIONS (Presenting author underlined)

1. Overman RA, Brookhart MA, Gourlay ML, Layton BJ, Farley JF, Deal, CL. “Oral glucocorticoid and anti-osteoporosis medication use in commercially insured Americans (2001-2011).” ISPE International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE). Boston, MA. August 22-26, 2015.

2. Olesiuk WJ, Farley JF, Ellis AR, Lichstein JC, Beadles CA, Morrissey JP, Dubard A, Jackson C, Domino ME. “Do medical homes offer improved diabetes care for Medicaid enrollees with co-occuring schizophrenia?” Academy Health 2015 Annual Research Meeting. Minneapolis, MN. June 14-16, 2015.

3. Lauffenburger JC, Farley JF, Gehi AK, Rhoney DH, Brookhart MA, Fang G. “Utilization of anticoagulants in atrial fibrillation: influence of clinical risk scores in real-world practice” ISPE International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE). Taipei, Taiwan. October 24-27, 2014.

4. Wang CC, Wu CH, Farley JF. “Patterns of pharmacological treatment for osteoporosis among patients qualified for pharmacotherapy according to national osteoporosis foundation guidelines” ISPE International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE). Taipei, Taiwan. October 24-27, 2014.

5. Beadles CA, Farley JF, Ellis AR, Lichstein JC, Morrissey JP, DuBard AC, Domino ME. “Do Medical Homes Increase Medication Adherence for People with Multiple Chronic Conditions?” Academy Health 2014 Annual Research Meeting. San Diego, CA. June 8-10, 2014.

6. Roberts AW, Dusetzina SB, Farley JF. “Implications of Washout Period Duration in Incident User Study Designs in Commercially Insured Populations” American Pharmacists Association Annual Meeting, Orlando, FL, March 28-31, 2014.

7. Desai RJ, Rao JK, Hansen RA, Maciejewski ML, Fang G, Farley JF. “Cardiovascular Diseases In Rheumatoid Arthritis: Can Early Treatment With Disease-Modifying Antirheumatic Drugs Alter The Risk”. American College of Rheumatology/ Association of Rheumatology Health Professionals Annual Meeting. San Diego, CA, October, 27, 2013.

8/4/2015

9

8. Maciejewski ML, Hansen RA, Powers BJ, Sanders L, Farley JF, Voils CI, Sleath B. “Prescriber Continuity and Medication Adherence for Complex Patients” Academy Health 2013 Annual Research Meeting. Baltimore MD, June 25, 2013.

9. Mayer CL, Lauffenburger JC, Farley JF, Brouwer K, Fried M, Hawke RL. “Medication use in patients with chronic Hepatitis C (HCV) from a U.S. commercial claims database: Inadequacy of prescribing information for assessment of potential drug interactions.” American Association for the Study of Liver Diseases (AASLD) 63rd Annual Meeting, Boston, MA, November 9-13, 2012.

10. Sikich L, Christian R, Sheitman B, Barnhill J, Chrisman A, Palmes G, Wegner L, McKee J, Farley JF, Wei D, Trygstad T, Wegner S. “A public health approach for increasing physician awareness of antipsychotic risks in youth” American Academy of Child and Adolescent Psychiatry 59th Annual Meeting, San Francisco, CA, October 23-28, 2012.

11. Christian RB, Farley JF, Wei D, Trygstad T, Sheitman B, Pfeiffenberger T, Sikich LM. (2012) “Antipsychotics- Keeping it Documented for Safety (A+KIDS): Initial experience and findings from a state medication Registry.” International Society for Pharmacoepidemiology (ISPE) 28th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Barcelona, Spain, August 22-26, 2012

12. Ellis A, Dusetzina SB, Hansen RA, Gaynes B, Farley JF, Sturmer T. “Comparison of Propensity-Score-Weighted and -Matched Estimates in a Comparative Effectiveness Study: A Demonstration Using STAR*D Trial Data”. International Society for Pharmacoepidemiology (ISPE) 28th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Barcelona, Spain, August 22-26, 2012

13. Maciejewski ML, Powers BJ, Sanders L, Farley JF, Hansen RA, Sleath B, Voils CI. “Implications of the continuity of medication management for the medical home of complex patients” Academy Health 2012 Annual Research Meeting, Orlando, FL, June 24-26, 2012.

14. Wu CH, Farley JF, Gaynes BN. “The association between antidepressant dosage titration and medication adherence among patients with depression.” American Pharmacists Association Annual Meeting, New Orleans, LA, March 9-12, 2012.

15. Branham AR, Robertson SL, Locklear A, Farley JF, Robinson MD, Dobson A, Rhodes CW. “The evaluation of a pharmacist intensive diabetes management program following implementation of physician-supported protocol.” 45th Annual Society for Teachers in Family Medicine Annual Spring Conference, Seattle, WA, April 25-29, 2012.

16. Ellis A, Dusetzina SB, Hansen RA, Gaynes B, Farley JF, Sturmer T. “Propensity Scores from Logistic Regression Yielded Better Covariate Balance Than Those from a Boosted Model: A Demonstration Using STAR*D Data.” International Society for Pharmacoepidemiology (ISPE) 27th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Chicago IL, August 14-17, 2011.

17. Wang CC, Wei DW, Farley JF. Impact of Monthly Prescription Cap on Medication Persistency among Patients with Hypertension, Hyperlipidemia, or Diabetes. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual International Meeting, Baltimore, MD, May 21-25, 2011.

18. Dorn SD, Wei D, Shah ND, Farley JF, Shaheen NJ, Sandler RS, Kappelman M. Impact of the 2008-2009 Economic Recession on Colonoscopy Utilization Among the Insured.

8/4/2015

10

Digestive Disease Week, “Quality of Life and Economic Analysis of GI Disorders” session, Chicago, IL, May 7, 2011.

19. Maciejewski ML, Farley JF, Wansink D. Turning the tide? Medication Adherence after Copayment Reductions. Academy Health 2010, “Strategies to Manage Utilization: Impact on Cost, Access, and Outcomes” session Annual Research Meeting, Boston, MA, June 27-29, 2010.

20. Dusetzina SB, Hansen RA, Farley JF, Sleath B, Weinberger M, Gaynes B. Bipolar Spectrum Disorders in Commercially Insured Children: Prevalence of Diagnoses and Treatments Received. Academy Health, “Children’s Mental Health Services” session, 2010 Annual Research Meeting, Boston, MA, June 27-29, 2010.

21. Maciejewski ML, Farley JF, Wansink D. Turning the tide? Medication adherence after copayment reductions. Society of General Internal Medicine 33rd Annual Meeting, Minneapolis, MN, April 30, 2010.

22. Farley JF. Medicaid Prescription Copayment Policies and Mental Health Outcomes in Schizophrenia. American Pharmacists Association Annual Meeting, Washington, DC, April 12 to 15, 2010.

23. Dorn S, Farley JF, Hansen RA, Shah N, Sandler R. The Effect of Direct to Consumer Advertisement and Physician Promotion of Tegaserod (Zelnorm) on Physician Visits, Diagnoses, and Prescriptions for Irritable Bowel Syndrome and Constipation. Digestive Disease Week 2009 - Health Services Research Forum, Chicago, IL, May 31, 2009.

24. Dusetzina S, Farley JF, Hansen RA. Relationship between State Medicaid Copayment Policies and Prescription Drug Utilization and Expenditures. Southern Pharmacy Administration Conference, Little Rock, AR, June 15-17, 2007.

25. Farley JF. Payment and Utilization Effects of a Step Therapy Prior Authorization Program for Atypical Antipsychotic Medications. American Pharmacists Association Annual Meeting, San Francisco, CA, March 17 to 21, 2006.

26. Devine JW, Farley JF, Hadsall R. Distribution and Determinants of Prescription Medication Use Among Individuals with Headache in the United States. American Pharmacists Association, Orlando Annual Meeting, Fl, April 1 to 5, 2005.

27. Farley JF, Cline RR, Gupta K. An Examination of Racial Variations in Prescribing of Antiresorptive Medications using the 2000 Medical Expenditure Panel Survey (MEPS). Annual Meeting of the American Pharmacists Association, Orlando, Fl, April 1 to 5, 2005.

28. Cline RR, Farley JF, Hansen RA, Schommer JC. Osteoporosis beliefs and antiresorptive medication use. American Pharmacists Association Annual Meeting, Seattle, WA, March 26 to 30, 2004.

PEER REFEREED POSTER PRESENTATIONS

1. Skinner A.C, Ringwalt C, Sachdeva N, Roberts A.W, Farley JF, Moss L.A, Weaver M. “Reducing opioid misuse: Evaluation of a Medicaid Lock-In Program.” Academy Health 2015 Annual Research Meeting, Minneapolis, MN; June 14-16, 2015.

8/4/2015

11

2. Skinner A.C, Ringwalt C, Sachdeva N, Roberts A.W, Farley JF, Moss L.A, Weaver M. “Obtaining opioids through circumvention of the Medicaid program: Effect of a narcotic lock-in program.” Academy Health 2015 Annual Research Meeting, Minneapolis, MN; June 14-16, 2015.

3. Domino ME, Ellis AR, Lichstein JC, Beadles C, Farley JF, Morrissey JP, Olesiuk WJ, Dubard A, Jackson C. “Use of primary care and specialty mental health services among patients with severe mental illness enrolled in a primary care medical home” Academy Health 2015 Annual Research Meeting. Minneapolis, MN. June 14-16, 2015.

4. Roberts AW, Farley JF, Holmes GM, Oramasionwu CU, Sleath BL, Skinner AC. “Minding the lock-in: Investigating characteristics associated with circumventing a Medicaid controlled substance lock-in program”. American Pharmacists Association Annual Meeting. San Diego, CA. March 27-30, 2015.

5. Beadles CA, Voils CI, Crowley MJ, Farley JF, Maciejewski ML. “Continuity of Medication Management and Continuity of Care: Conceptual and Operational Considerations.” Academy Health 2014 Annual Research Meeting. San Diego, CA. June 8-10, 2014.

6. Roberts AW, Crisp GD, Esserman DA, Roth MT, Weinberger M, Farley JF. “Patterns of adherence and health service utilization among UNC health care pharmacy assistance program enrollees with chronic disease”. American Pharmacists Association Annual Meeting. Orlando, FL. March 29-31, 2014.

7. Lauffenburger JL, Brookhart MA, Farley JF, Rhoney DH, Gehi AK, Fang G. “Dabigatran and warfarin for stroke prevention in atrial fibrillation: factors associated with use following new market entry in real-world patients.” American Pharmacists Association Annual Meeting. Orlando, FL. March 29-31, 2014.

8. Robertson S, Branham AR, Locklear A, Farley JF, Robinson M, Dobson LA, Rhodes CW. “The evaluation of a pharmacist asthma management program following implementation of physician supported protocol.” American Pharmacists Association Annual Meeting, New Orleans, LA, March 9-12, 2012.

9. Dusetzina SB, Gaynes BN, Weinberger M, Farley JF, Sleath B, Hansen RA. “The quality of initial pharmacotherapy for children with bipolar I disorder.” International Society for Pharmacoepidemiology (ISPE) 27th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Chicago, IL, August 14-17, 2011.

10. Lauffenburger JC, Farley JF. Four-dollar Generic Drug Discount Plans: A review of Changes in Quality Management, Access, and Prescription Utilization. Academy Health 2011 Annual Research Meeting, Seattle WA, June 12-14 2011.

11. Farley JF, Wansink D, Lindquist HH, Parker J, Maciejewski ML. Sustained and Targeted Medication Adherence Improvements Associated with Value Based Insurance Design. Academy Health 2011 Annual Research Meeting, Seattle WA, June 12-14, 2011.

12. Maciejewski ML, Wansink D, Lindquist JH, Parker J, Farley JF. Health Care Costs Associated with Value Based Insurance Design. Academy Health 2011 Annual Research Meeting, Seattle WA, June 12-14, 2011.

13. Ellis A, Dusetzina SB, Hansen GA, Gaynes B, Farley JF, Sturmer A. Propensity Scores from Logistic Regression Yielded Better Covariate Balance Than Those from a Boosted

8/4/2015

12

Model: A Demonstration Using STAR*D Data. Academy Health 2011 Annual Research Meeting, Seattle WA, June 12-14, 2011.

14. Wu CH, Farley JF. The Influence of Comorbid Anxiety on Medication Use and Service Utilization among Patients with Major Depressive Disorder: Results from a Retrospective Claims Database. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual International Meeting, Baltimore, MD, May 21-25, 2011.

15. Farley JF, Hansen RA, Yu-Isenberg K, Maciejewski ML. The Effect of Antipsychotic Adherence on Adherence to Diabetes, Hyperlipidemia, and Hypertension Medications and Associated Health Service Utilization and Expenditures. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual International Meeting, Baltimore, MD, May 21-25, 2011.

16. Farley JF, Hansen RA, Yu-Isenberg KS, Maciejewski ML. Trends and Predictors of Antipsychotic Adherence in Medicaid Patients with Schizophrenia: The Role of Comorbidity. American Psychiatric Association 2011 Annual Meeting, Honolulu, HI, May 14-18, 2011.

17. Wang CC, Farley JF. The Effect of Adjunctive Psychotherapy on Medication Adherence among Patients with Schizophrenia. American Pharmacists Association, Washington, DC, March 25 to 28, 2011.

18. Farley JF, Hansen RA. Disruptions in antipsychotic adherence are jointly associated with reduced adherence for other chronic conditions. International Society for Pharmacoeconomics and Outcomes Research International Meeting, Atlanta, GA, May 15-19, 2010.

19. Dusetzina S, Hansen RA, Farley JF, Sleath B, Weinberger M, Gaynes B. Age related treatment differences among children with bipolar spectrum disorders. International Society for Pharmacoeconomics and Outcomes Research International Meeting, Atlanta, GA, May 15-19, 2010.

20. Wang CC, Farley JF. The Effect of Adjunctive Psychotherapy on Hospitalizations among Patients with Schizophrenia. American Pharmacists Association Annual Meeting, Washington, DC, April 12 to 15, 2010.

21. Katz AJ, Ryan PB, Farley JF. Impact of state Medicaid preferred drug list policies on total medical expenditures and patient outcomes. Drug Information Association 45th Annual Meeting, San Diego, CA, June 21-25, 2009.

22. Wang CC, Farley JF, Biddle A. Cost-effectiveness of ezetimibe/simvastatin versus simvastatin: Will the increased risk of cancer make ezetimibe/simvastatin an inappropriate treatment choice? International Society for Pharmacoeconomics and Outcomes Research International Meeting, Orlando, FL, May 16-20, 2009.

23. Hansen RA, Farley JF, Droege M, Maciejewski M. A comparison of economic outcomes between adherent and nonadherent patients treated with oral anti-diabetic medications. International Society for Pharmacoeconomics and Outcomes Research International Meeting, Orlando, FL, May 16-20, 2009.

24. Wang CC, Farley JF. Patterns and Predictors of Antipsychotic Medication Use among the U.S. population: Findings from the Medical Expenditure Panel Survey (MEPS). American Pharmacists Association Annual Meeting, San Antonio, TX, April 3-6, 2009.

8/4/2015

13

25. Dusetzina S, Farley JF. The Influence of Medicare Part D on Medicaid Prescription Expenditures and Utilization. American Pharmacists Association Annual Meeting, San Diego, CA, March 14-17, 2008.

26. Devine JW, Hadsall RS, Farley JF. Extending Matching Estimators of Causal Effects to Consider Unobserved Variable Bias: An Application of Sensitivity Analysis. Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Philadelphia, PA, May 20-24, 2006.

27. Farley JF. A Comparison of the Elixhauser and Charlson Indices to Control for Confounding in Health Outcomes Studies. Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Washington, D.C. May 15 to 18, 2005.

28. Farley JF, Cline RR, Schommer JC. Prior Authorizations and Potential Spillover Effects. Poster presentation at the 2004 Midwest Pharmacy Administration Conference, Purdue University, July 29 to August 1, 2004.

29. Farley JF, Cline RR, Hansen RA. Resorptive drug use patterns among Minnesota females: results of a statewide survey. American Pharmacists Association Annual Meeting, Seattle, WA, March 26 to 30, 2004.

30. Farley JF, Hadsall R, Novak J. Perceptions and reporting of errors in community pharmacy practice. American Pharmacists Association Annual Meeting, New Orleans, LA, March 28 to April 1, 2003.

NON-PEER REFEREED PUBLICATIONS AND PRESENTATIONS Editorials 1. Farley JF. (2010) Containing cost despite the cost. Medical Care. 48(1):1-3. Publications

1. Zlott D, Farley JF, Guidotti M. (2014) Association Report on Specialty Pharmacy: Implications for medication expenditures and pharmacy practice. Journal of the American Pharmacists Association. 54:578-582.

2. Weitzel K, Farley JF, Anderson JJ, Whisman TR (2007) APhA 2007 House of Delegates: Improving practice today, preparing for and protecting the profession’s future. Journal of the American Pharmacists Association. 47(5):548-562.

3. Farley JF, Taluja A, Shah B, Varkey A. (2007) “Where are you going after graduation? Survey on postgraduate training can help your decision process” Student Pharmacist. 3(1): 24-25.

4. Farley JF, Taluja A, Shah B, Varkey A. (2006) Officers detail how postgraduate experience enhances career, profession. Student Pharmacist. 2(2): 28.

Legislative Reports

8/4/2015

14

1. Christian R, Farley JF, McKee J, Moran K, Pfeiffenberger T, Pikoulas T, Sampson C, Sheitman B, Thompson-Schwartz CM, Trygstad T, Weeks L, Wegner S. (2014) Antipsychotics – Keeping It Documented for Safety (A+KIDS) Adult Safety with Antipsychotic Prescribing (ASAP) Effectiveness Report. North Carolina Department of Health and Human Services. S.L. 2013-360, Section 12H.28 (a) and (b).

Non-Peer Refereed Presentations: Conference Invitations and Continuing Education

1. “Designing Medication Copayments to Improve Adherence and Health Outcomes: The Role of Value Based Insurance Design” Presented at the North Carolina Alliance for Health Communities 13th Annual Education Conference, Cary, NC, October 30, 2013.

2. “Economic Social and Administrative Sciences Research Roundtables: Strategies to Improve Studies Using Secondary Databases” Presented at the American Pharmacists Association Annual Meeting, Los Angeles, CA, March 2, 2013.

3. “Applications of Pharmaceutical Comparative Effectiveness Research Using Large Databases: Copayment Incentives and Medication Adherence.” Presented at the Sixth Annual Chapel Hill Drug Conference, Comparative Effectiveness Research: Methods and Applications Session, Chapel Hill, NC, May 12, 2011.

4. “Trends and Determinants of Prescription Anti-osteoporosis Medication Use.” Presented at the American Society of Health-System Pharmacists Midyear Clinical Meeting, ASHP Donor Matching Reception, Las Vegas, NC, December 5, 2009.

5. "Osteoporosis Therapy: Who Uses It and How Much Does It Cost?" Presented at the American Society of Health-System Pharmacists Midyear Clinical Meeting, Las Vegas, NV, December 8, 2009.

6. “The effect of Medicaid Prescription Restrictions on Mental Health Utilization and Expenditures in Patients with Schizophrenia”. Presented at the Pfizer Medical Futures Forum, New York, NY, March 26, 2009.

7. “Learning from the past: historical errors in ethical judgment” Presented at the Mountain Area Health Education Center 12th Annual Bioethics conference titled “What would Hippocrates Say? Bioethics for the New Millennium” Asheville, NC, August 7, 2007.

8. “Racial variation in antiresorptive medication use: results from the 2000 Medical Expenditure Panel Survey (MEPS)” Presented to the American College of Clinical Pharmacy symposium entitled “Research conducted with publicly available, population-based surveys: Learn from the experts” Memphis, TN, April 24, 2007.

9. “Follow-On Biologics: Policy Implications … The Next Generics?” Presented to Fellows of the American Pharmacists Association at the “2006 Fellow Think Tank” San Francisco, CA, March 20th, 2006.

Invited Presentations – University of North Carolina

8/4/2015

15

1. “Claims-Based Measures of Medication Adherence and Methodological Issues.” NC TraCS Comparative Effectiveness Research (CER) Strategic Initiative: Medication Adherence Seminar Series. July 18, 2014.

2. “Designing Medication Copayment Policies to Improve Value in Health for Patients with Chronic Health Conditions.” School of Nursing, T-32 Nursing Seminar. November 15, 2011.

3. “Pediatric antipsychotic medication use in the North Carolina Medicaid program and the A+KIDS registry.” University of North Carolina/Duke University Program in Mental Health Services & Systems Research Postdoctoral Training Program Seminar. April 5, 2011.

4. “Antipsychotic cost-containment strategies in state Medicaid programs.” University of North Carolina/Duke University Program in Mental Health Services & Systems Research Postdoctoral Training Program Seminar. October 9, 2007.

Invited Presentations – External Academic Institutions 1. “Managing multiple chronic conditions and medication adherence in patients with serious

mental illness”. Duke University School of Medicine, Department of Psychiatry, Psychiatry Residency Training Seminar. August 14, 2014.

2. “The use of a registry to improve antipsychotic prescribing and monitoring: The case of A+KIDS” Durham VAMC, Center for Health Services Research. February 12, 2013.

ACADEMIC/ TEACHING RECORD UNC Eshelman School of Pharmacy

Term Course number, title, type Approximate Enrollment

Teaching Responsibility

Spring 2015 DPOP 870, Pharmaceutical Outcomes Research, 3 credit required PhD course

15 Instructor 1 lecture hours

Fall 2014 DPOP 806: Pharmaceutical Policy, 3 credit required Ph.D. course and PharmD elective

11 Course Director

26 lecture hours

Fall 2014 PHCY 801, Ethical Dilemmas in Translational Research


Fall 2013 PHCY 801, Ethical Dilemmas in Translational Research


8/4/2015

16

Fall 2013 PHCY 431, Introduction to Health Systems, 3 credit required PharmD course


Fall 2013 PHCY 433, Drug Literature Analysis and Interpretation, 3 credit required PharmD course


Spring 2013 DPOP 870, Pharmaceutical Outcomes Research, 3 credit required PhD course



165 Instructor 1 lecture hour



Fall 2012 DPOP 806: Pharmaceutical Policy, 3 credit required Ph.D. course and PharmD elective

12 Course Director

26 lecture hours

Spring 2012 DPOP 899, Pharmaceutical Outcomes and Policy Seminar, 1 credit required Ph.D. course

4 Course Director 3 lecture hours





Fall 2011 DPOP 899, Pharmaceutical Outcomes and Policy Seminar, 1 credit required Ph.D. course

4 Course Director 1 lecture hour

Spring 2011 DPOP 899, Pharmaceutical Outcomes and Policy Seminar, 1 credit required Ph.D. course

6 Course Director 2 lecture hours

Spring 2011 PHCY 432, Pharmacy Law and Ethics, 3 credit required PharmD course




Fall 2010 DPOP 899, Pharmaceutical Outcomes and Policy Seminar, 1 credit required PhD course

6 Course director 2 lecture hours

Fall 2010 DPOP 806, Pharmaceutical Policy, 3 credit required PhD course and PharmD elective


Spring 2010 PHCY 432, Pharmacy Law and Ethics, 3 credit 145 Course director 13 lecture hours

8/4/2015

17

required PharmD course













Spring 2007 DPOP 801, Pharmaceutical Economics, 3 credit required PhD course


Spring 2007 DPOP 899, Pharmaceutical Outcomes and Policy Seminar, 1 credit required PhD course




Residency Instruction UNC Eshelman School of Pharmacy Community Pharmacy Residency Program 2012 – 2014 Instructor, Observational Study Design: Practical Considerations Graduate and Doctor of Pharmacy Students Supervised UNC Eshelman School of Pharmacy Pharmaceutical Outcomes and Policy Ph.D. Program Research Advisor 2015 – Present Nirosha Mahendraratnam – Thesis: TBD. (Expected graduation May

2018)

2013 – Present Mrudula Borse – Thesis: “Impact of Mechlorethamine Shortage on Drug Utilization and Cancer Related Outcomes”. (Expected graduation May, 2016)

8/4/2015

18

2011 – Present Andrew Roberts – Thesis: “Locked In: Evaluating the Design and Outcomes of a North Carolina Medicaid Controlled Substance Policy”. (Expected graduation May, 2015)

2011 – 2013 Rishi Desai (co-advisor with Jaya Rao) – Thesis: “TNF-alpha Inhibitor Treatment and the Risk of Atherosclerotic Events in Patients with Rheumatoid Arthritis”. (Completed March 28, 2013)

2010 – 2012 Aaron Katz – Thesis: “Use, Effectiveness, and Safety of bevacizumab in older adults with advanced non-small cell lung cancer.” (Completed November 29, 2012)

2009 – Present Jonas Daugherty (Part time enrollment) – Thesis: “The Impact of Pharmaceutical Manufacturer Coupons on Medication Use and Cost among Lipid Lowering Agents”. (Expected Graduation May 2016)

2009 – 2012 David Wei – Thesis: “Economic Evaluation of Biological Therapy Use among Patients with Crohn's Disease.” (Completed June, 28 2012)

2007 – 2011 Chi-Chuan (Emma) Wang – Thesis: “The Effect of Adjunctive Psychotherapy on Health Related Outcomes among Patients with Schizophrenia.” (Completed May, 2011)

UNC Eshelman School of Pharmacy Pharmaceutical Outcomes and Policy Ph.D. Dissertation Committee Member Julie Lauffenburger (Dissertation Chair) – Thesis: “Anticoagulant Use in Atrial Fibrillation: “Use, Switching, and Clinical Effects in Real-World Patients” (Completed, September 2014)

Patrick Ryan – Thesis: “Enhancing Drug Safety through Active Surveillance of Observational Healthcare Data” (Completed, April 2011)

Brian Leinwand – Thesis: “The Cost-Effectiveness of Treatments for Pediatric ADHD: The Effects of Gender and Comorbidity” (Completed, April 2011)

Stacie Dusetzina – Thesis: “Diagnosis and Treatment of Pediatric Bipolar Disorder in a Commercially Insured Population” (Completed, May 2010)

Melissa Butler – Thesis: “The role of patient activation in Medicare prescription drug coverage information seeking.” (Completed August, 2009)

Shi-Yen (Sharon) Chen – Thesis: “Second-generation antidepressant use in treatment for major depressive disorder - an examination of guideline components and healthcare utilization.” (Completed October, 2008).

UNC Gillings School of Global Public Health: Health Policy and Management Master’s Thesis Committee Member 2015 Tomi Ogunwumiju – Thesis: Medical Home Use and Medication

Adherence in Patients with Comorbid Schizophrenia and Hypertension. (Completed April, 2015).

8/4/2015

19

2013 Molly McIntyre – Thesis: Use of antipsychotics in NC Medicaid Foster Care Population. (Completed April, 2013)

2013 Krutika Amin – Thesis: Do baseline adherence and frequent emergency department use predict medication adherence changes: An analysis of NC Medicaid Policy Changes (Completed April, 2013)

2012 Kathleen Moran – Thesis: The association of Medicaid and opioid prescribing. (Completed April, 2012)

UNC Eshelman School of Pharmacy – PharmD Honors Program Advisor 2014 – 2015 Victoria “Marti” Guidotti – Honors Paper: Randomized controlled trial of

an emergency department care coordination program for patients with chronic non-cancer pain: analysis of emergency department cost savings

Post-Doctoral Advisor 2010 – 2012 Chung-Hsuen (Alvin) Wu. Humana/Competitive Health Analytics/UNC

Pharmaceutical Outcomes Post-Doctoral Research Fellowship UNC Eshelman School of Pharmacy Pharmaceutical Outcomes and Policy Ph.D. Student Advisory Committee Member 2015 – Present Nirosha Mahendraratnam (Expected graduation May 2018) 2014 – Present Yi-Ting (Zoey) Chou (Expected graduation May 2017) 2012 – 2014 Mrudula Borse (Expected graduation May 2016) 2012 – 2013 Stedman Stevens (Completed Masters May 2013) 2011 – 2013 Andrew Roberts (Expected graduation May 2015) 2010 – 2012 Julie Lauffenburger (Graduated September 2014) 2010 – 2011 Melea Ward (Graduated December 2013) 2009 – 2011 Mesnad Almutairi (Completed Masters Jan 2012) 2009 – 2011 Rishi Desai (Graduated May 2013) 2009 – 2011 Anne Beaubrun (Graduated May 2013) 2008 – 2009 Brian Leinwand (Graduated May 2011) 2008 – 2010 Patrick Ryan (Graduated May 2011) 2008 – 2009 Stacie Dusetzina (Graduated May 2010) UNC Eshelman School of Pharmacy Pharmaceutical Outcomes and Policy Ph.D. Research Practicum Advisor Mrudula Borse – “Accuracy of prescription claims database in identifying truly non-adherent patients” (Completed May 2014)

Robert Overman – “Fracture rates in chronic glucocorticoid users” (Completed May 2014)

Andrew Roberts – “Implications of drug-free period duration in the new user observational study design” (Completed May 2013)

8/4/2015

20

Julie Lauffenburger (co-advisor Mary Roth) – “Four dollar generics – their impact on quality assurance” (Completed May 2012)

Jonas Daugherty – “A descriptive analysis of pharmaceutical manufacturer use in the dyslipidemia market” (Completed May 2011)

Anne Beaubrun – “Predialysis Care as a Predictor of Hospitalization Rates and Mortality in End Stage Renal Disease Patients: Assessing Variations by Race” (Completed May 2011)

Stacie Dusetzina – “Medicaid prescription drug utilization and expenditures following Part D.” (Completed May 2009)

Chi-Chuan Wang – “Patterns and Predictors of Antipsychotic Medication Use among the U.S. population: Findings from the Medical Expenditure Panel Survey (MEPS).” (Completed May 2008)

Brian Leinwand (co-advisor Richard Hansen) – “Geographic Information System Mapping – A Useful Tool for Pharmacy Business Planning (Completed May 2008)

UNC Eshelman School of Pharmacy Resident Teaching Certificate Program Advisor 2014 – 2015 Jade Young, PGY-1, Community Care North Carolina/Vidant 2013 – 2014 Lucas Berenbrok, PGY-1, Kerr Drug 2012 – 2013 Amanda Hollar, PGY-1, Kerr Drug 2011 – 2012 Kristen James,PGY-1, AccessCare 2010 – 2011 Kajal Bhika, PGY-1, PPD 2009 – 2010 Ashley Branham, PGY-2 Moose Pharmacy 2009 – 2010 Whitney Maxwell, PGY-2, UNC Hospitals UNC Eshelman School of Pharmacy Pharm.D. Faculty Advisor 2010 – 2011 PY1 Class of 2014, Pharm.D. Faculty Advisor 2009 – 2010 PY1 Class of 2013, Pharm.D. Faculty Advisor GRANTS AND CONTRACTS Grants No Number Trygstad (PI) 9/01/2014 – 8/30/2017 Center for Medicare and Medicaid Innovations Grant – Subcontract to CCNC Optimizing the Medical Neighborhood: Transforming Care Coordination through the North Carolina Community Pharmacy Enhanced Services Network This contract will assist CCNC in implementing an innovative new care delivery and payment model that integrates community pharmacy-provided medication management strategies into existing patient-centered care teams, e.g. medical homes and neighborhoods, while incentivizing the pharmacist to address gaps in care. Role: Institutional co-PI Total direct UNC costs = $1,156,142 Percent effort = 40% 1RO1HS023099-01 Farley (PI) 6/01/2014 – 11/30/2015 Agency for Healthcare Research and Quality (AHRQ)

8/4/2015

21

Continuity of Medication Management in Medicaid This study describes continuity of medication management in Medicaid patients with severe mental illness being treated for one of three chronic conditions (diabetes, hypertension, and hyperlipidemia) and its effect on medication adherence and health service utilization Role: PI Total direct UNC costs = $281,365 Percent effort = 20% 1R21AG043668-01A1 Fang (PI) 7/01/2013 – 06/30/2015 National Institutes of Health – National Institute on Aging Should the Elderly Have Lower Dose of ACE Inhibitors for Secondary Prevention after AMI? This retrospective observational cohort study will compare the real-world treatment effectiveness and safety of the established RCT doses of ACE inhibitors post AMI versus lower doses in the elderly. Role: co-Investigator Total direct UNC costs = $263,720 Percent effort = 8% CDC-NCIPC U01 20120502 Skinner (PI) 10/01/2012 – 09/30/2014 National Center for Injury Prevention and Control (NCIPC) Change in Opioid Use and Overdose After a Medicaid Lock-in Program This evaluation will determine the effectiveness of a Medicaid lock-in program designed to reduce misuse of controlled substance prescription drugs. Role: co-Investigator Total direct UNC costs = $283,408 Percent effort = 5% NC TraCS Institute Farley (PI) 06/01/2012 – 05/30/2013 North Carolina Translational and Clinical Science (TraCS) Institute Grant A Programmatic Description of the UNC Charity Care Pharmacy Assistance Program This study will examine a population of patients receiving prescriptions through the UNC pharmacy assistance program focusing on the population being served, the prescription services utilized, and the effect of the program on medication adherence and health service utilization. Role: Principal Investigator Total direct UNC costs = $35,891 Percent effort = 0% 1 R24 HS019659-01 Domino (PI - Subcontract) 09/30/2010 – 09/29/2012 North Carolina Community Care of Networks, Inc. via AHRQ Expansion of Research Capabilities to Study Comparative Effectiveness in Complex Patients. The goal of this grant is to link HEARTS inpatient psychiatric hospital service data, IPRS outpatient mental health service data, and Medicaid claims data to capture a more complete picture of psychiatric illness in North Carolina to examine health outcomes among patients receiving services in a medical home network. Role: Co-Investigator Total direct UNC costs = $136,606 Percent effort = 5% 1 R21 HS19445-01 Maciejewski M (PI) 09/01/2010 - 08/31/2012 Agency for Healthcare Research and Quality Continuity of Medication Management (COMM). The goal of this grant is to examine the effect of continuity of medication management provided my physicians for patients with multiple chronic conditions on medication adherence and health utilization and expenditures. Role: Site Principal Investigator Total direct UNC costs = $83,549 Percent effort = 15% Robert Wood Johnson Foundation Maciejewski M (PI) 04/01/2010 - 03/30/2011 Health Care Financing and Organization (HCFO) Grant

8/4/2015

22

The Patient and System Benefits of Value-based Insurance Design The goal of this grant is to examine the impact of waiving medication copayments on medication adherence and health outcomes in patients using medication for chronic medical conditions. Role: Site Principal Investigator Total direct UNC costs = $17,965 Percent effort = 15% Pfizer Scholars Grant in Health Policy Farley (PI) 07/01/2007 - 06/30/2009 The Effect of Medicaid Prescription Restrictions on Mental Health Utilization and Expenditures in Patients with Schizophrenia. The goal of this project was to examine the influence of Medicaid prescription cost-containment policies on medication adherence and health outcomes in patients with schizophrenia. Role: Principal Investigator Total direct costs = $130,000 Percent effort = 50% ASHP Foundation Junior Investigator Grant Farley (PI) 05/01/2007 - 10/31/2008 Anti-osteoporosis Medication Trends and Determinants in the U.S. Ambulatory Population from 1996 to 2004: Results from the Medical Expenditure Panel Survey (MEPS). The goal of this project was to determine the patterns and predictors of anti-osteoporosis medication use in the U.S. among patients in the ambulatory setting. Role: Principal Investigator Total direct costs = $16,667 Percent effort = 8% Contracts Contract (Farley) 1/1/2013 – 6/30/2013 North Carolina Community Care Networks Report of the CheckMeds Program The major goal of this contract was to evaluate the CheckMeds program in North Carolina to provide recommendations to the Office of Rural Health related to optimal data capture and reporting for the purpose of ongoing operations and formal evaluation capabilities. Role: PI Total direct UNC costs = $14,881 Percent effort = 20% Contract (Farley) 7/1/2012 – 6/30/2014 North Carolina Community Care Networks A+KIDS – Antipsychotics in KIDS (Keeping it Documented for Safety) Extension The major goal of this contract is to evaluate the effect of a pediatric antipsychotic registry on metabolic screening and antipsychotic utilization in the NC Medicaid population. Role: PI Total direct UNC costs = $122,363 Percent effort = 20% Contract (Farley) 4/1/2012 – 9/29/2012 Community Care North Carolina Expansion of Research Capability to Study Comparative Effectiveness in Complex Patients This contract is an extension of the AHRQ research grant R24 HS019659-01 and was granted to better understand the role of engagement in a medical home model on the care of patients with chronic health conditions discharged from psychiatric hospitals. Role: Principal Investigator Total direct UNC costs = $73,299 Percent effort = 20% Contract (Farley) 12/1/2010 – 6/30/2012 AccessCare North Carolina A+KIDS – Antipsychotics in KIDS (Keeping it Documented for Safety)

8/4/2015

23

The major goal of this contract is to assist in the implementation and initial evaluation of a pediatric antipsychotic medication registry implemented in the NC Medicaid population. Role: Principal Investigator Total direct UNC costs = $58,051 Percent effort = 20% Contract (Maciejewski M – PI) 8/05/2008-02/28/2009 Blue Cross Blue Shield of North Carolina (BCBSNC). Medication Dedication Evaluation The goal of this contract was to assist BCBSNC with designing metrics of medication adherence to evaluate the effect of their Medication Dedication program on their patient population. Role: Site Principal Investigator Total direct UNC costs = $25,303 Percent effort = 10% HHSA 290-2005-040I Gaynes B (PI) 07/15/2008 - 11/13/2009 AHRQ DEcIDE Contract: Addressing Knowledge Gaps in the Treatment of Depression. The goal of this project was to examine the influence of treatment selection in the STAR*D clinical trial on clinical outcomes among patients with depression. Role: Co-Investigator Total direct UNC costs: $246,425 Percent effort = 3% PROFESSIONAL SERVICE Service to Discipline Periodical Reviewer 2013 Pharmacoepidemiology and Drug Safety 2013 – 2015 Psychiatric Services 2011 General Hospital Psychiatry 2010 – 2013 Administration and Policy in Mental Health and Mental Health Services

Research 2010 – 2013 Annals of Internal Medicine 2010 Journal of the American Medical Association 2009 – 2010 Journal of Health Care for the Poor and Underserved 2009 – 2015 Health Affairs 2009 Medical Care 2008 – 2011 American Journal of Managed Care 2007 – 2011 Research in Social and Administrative Pharmacy 2007 Drugs in Aging 2007 Osteoporosis International 2007 – 2015 Journal of Managed Care Pharmacy 2005 – 2013 Journal of the American Pharmacists Association American Pharmacists Association 2015 – 2016 Chair: APhA Academy of Pharmaceutical Research and Science-

Economic, Social, and Administrative Sciences Section 2015 House of Delegates, Academy of Pharmaceutical Research and Science

(APRS) Delegate

8/4/2015

24

2014 – 2015 Chair Elect: APhA Academy of Pharmaceutical Research and Science- Economic, Social, and Administrative Sciences Section

2014 Reviewer: APhA 2015 Annual Meeting APRS-ESAS Contributed Papers 2013 Reviewer: APhA 2014 Annual Meeting APRS-ESAS Contributed Papers 2013 Judge: APhA 2013 Annual Meeting APRS-ESAS Contributed Paper

Podium Session: Best Paper Award 2011 – 2012 APhA 2012 Annual Meeting, APRS Economic, Social, and

Administrative Sciences Contributed Papers Review Committee Member 2010 – 2011 APhA 2011 Annual Meeting Economic, Social, and Administrative

Science (ESAS) Research Methods Planning Committee Member 2011 Reviewer: APhA 2012 Annual Meeting APRS-ESAS Contributed Papers 2010 Reviewer: APhA 2011 Annual Meeting APRS-ESAS Contributed Papers 2009 Reviewer: APhA 2010 Annual Meeting APRS-ESAS Contributed Papers 2008 Reviewer: APhA 2009 Annual Meeting APRS-ESAS Contributed Papers 2007 – 2008 Chair: 2008 Health Policy Forum Planning Committee 2007 House of Delegates, Academy of Pharmaceutical Research and Science

(APRS) Delegate 2006 – 2007 House of Delegates Policy Committee Member 2006 – 2007 Academy of Pharmaceutical Research and Science – Post Graduate

Officer 2006 House of Delegates, Academy of Pharmaceutical Research and Science

(APRS) Delegate 2005 – 2006 Academy of Pharmaceutical Research and Science- Economic, Social, and

Administrative Sciences Postgraduate Officer 2005 House of Delegates, Academy of Pharmaceutical Research and Science

(APRS) Delegate International Society for Pharmacoeconomics and Outcomes Research 2004 – 2005 President: ISPOR University of Minnesota Student Chapter 2003 – 2004 President elect: ISPOR University of Minnesota Student Chapter American Association of Colleges of Pharmacy (AACP) 2011, 2013, 2014 AACP Social and Administrative Science New Investigator Award (NIA)

Grant Reviewer Professional Memberships 2012 – Present Academy of Managed Care Pharmacy 2011 – Present American Association of Colleges of Pharmacy 2004 – Present Academy Health 2002 – Present American Pharmacists Association 2002 – Present International Society for Pharmacoeconomics and Outcomes Research Service to UNC-Chapel Hill

8/4/2015

25

UNC Eshelman School of Pharmacy Service 2014 Chair, Faculty Search Committee, Assistant Professor in Health

Informatics, Division of Pharmaceutical Outcomes and Policy/Carolina Health Informatics Program (CHIP)

2013 – present Faculty Advisor, International Society for Pharmacoeconomics and Outcomes Research, UNC Student Chapter

2013 – 2014 Director, UNC/GSK Pharmaceutical Outcomes Research Postdoctoral Fellowship

2013 Member, Curriculum Design and Execution Steering Committee, Pharmacy Innovation and Problem Solving (PIPS) subcommittee

2012 – 2013 Member, Curriculum Design and Execution Steering Committee, Introduction to Health Care, Policy, and Health Systems subcommittee

2012 – 2013 Member, Curricular Transformation Steering Committee, Immersion in Scientific Inquiry and Scholarship subcommittee

2012 – present Divisional Director of Graduate Studies (DDGS), Division of Pharmaceutical Outcomes and Policy, University of North Carolina, Eshelman School of Pharmacy

2012 – present Graduate Education Committee, University of North Carolina, Eshelman School of Pharmacy

2012 – 2013 Member, Curricular Transformation Steering Committee, Scholarship Subcommittee

2011 – present Faculty Advisor, Academy of Managed Care Pharmacy, UNC Student Chapter

2010 – 2011 Chair, Abstract Review Committee, Sixth Annual Chapel Hill Drug Conference on Comparative Effectiveness Research

2010 – 2011 Chair, Scientific Planning Committee, Sixth Annual Chapel Hill Drug Conference on Comparative Effectiveness Research

2010 – 2011 Faculty Search Committee, Assistant/Associate/Professor in the Division of Pharmaceutical Outcomes and Policy

2008 Coordinator, University of North Carolina, UNC Eshelman School of Pharmacy, Division of Pharmaceutical Outcomes and Policy Retreat

2007 – 2012 Admissions Committee, University of North Carolina, UNC Eshelman School of Pharmacy

2007 – 2009 Community Pharmacy Advisory Board Committee, University of North Carolina, UNC Eshelman School of Pharmacy

2007 – 2013 PharmD Admissions Interviewer, University of North Carolina, UNC Eshelman School of Pharmacy

Documents

Curriculum Vitae - UNC Eshelman School of Pharmacy€¦ · Curriculum Vitae . Joel F. Farley, ... (Chapter 6) in Principles of ... 2. Lauffenburger JC, Farley JF, Gehil AK, Rhoney